Symbols / ENOV Stock $24.10 +5.66% Enovis Corporation

Healthcare • Medical Devices • United States • NYQ
ENOV (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO Mr. Damien McDonald
Exch · Country NYQ · United States
Market Cap 1.39B
Enterprise Value 2.73B
Income -1.18B
Sales 2.25B
FCF (ttm) 104.43M
Book/sh 26.05
Cash/sh 0.64
Employees 7,802
Insider 10d —
IPO May 08, 2008
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 6.03
PEG 3.45
P/S 0.62
P/B 0.93
P/C —
EV/EBITDA 7.38
EV/Sales 1.21
Quick Ratio 0.80
Current Ratio 2.02
Debt/Eq 92.47
LT Debt/Eq —
EPS (ttm) -20.72
EPS next Y 4.00
EPS Growth —
Revenue Growth 2.60%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-02-26
ROA 1.09%
ROE -58.27%
ROIC —
Gross Margin 60.88%
Oper. Margin 6.09%
Profit Margin -52.69%
Shs Outstand 57.54M
Shs Float 56.44M
Insider Own 1.48%
Instit Own 117.30%
Short Float 17.79%
Short Ratio 11.60
Short Interest 8.58M
52W High 37.85
vs 52W High -36.33%
52W Low 21.00
vs 52W Low 14.76%
Beta 1.59
Impl. Vol. 41.33%
Rel Volume 0.75
Avg Volume 1.01M
Volume 751.26K
Target (mean) $44.73
Tgt Median $45.00
Tgt Low $33.00
Tgt High $55.00
# Analysts 11
Recom Strong_buy
Prev Close $22.81
Price $24.10
Change 5.66%
About

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$44.73
Mean price target
2. Current target
$24.10
Latest analyst target
3. DCF / Fair value
$32.67
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$24.10
Low
$33.00
High
$55.00
Mean
$44.73

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-06 main Evercore ISI Group Outperform → Outperform $35
2026-02-26 main BTIG Buy → Buy $43
2026-02-26 main Needham Buy → Buy $52
2026-01-06 init BTIG — → Buy $41
2025-12-17 main Canaccord Genuity Buy → Buy $50
2025-12-17 init Freedom Capital Markets — → Buy $45
2025-11-07 main Wells Fargo Overweight → Overweight $42
2025-08-08 main Canaccord Genuity Buy → Buy $58
2025-08-08 main UBS Buy → Buy $57
2025-08-08 main Wells Fargo Overweight → Overweight $41
2025-08-07 main Needham Buy → Buy $49
2025-07-08 main Evercore ISI Group Outperform → Outperform $46
2025-05-14 main Canaccord Genuity Buy → Buy $70
2025-05-09 main JMP Securities Market Outperform → Market Outperform $55
2025-05-09 main Needham Buy → Buy $57
2025-04-09 reit Needham Buy → Buy $64
2025-04-02 reit Needham Buy → Buy $64
2025-02-27 main Needham Buy → Buy $64
2024-11-07 reit Needham Buy → Buy $65
2024-10-03 init JMP Securities — → Market Outperform $62
News
RSS: Latest ENOV news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-31 ORTIZ CHRISTINE Director — 770 $0.00 $0
2026-03-13 ENGERT OLIVER Officer — 1,000 $23.74 $23,740
2026-03-10 ENGERT OLIVER Officer — 1,000 $23.93 $23,930
2026-03-09 MCDONALD DAMIEN Chief Executive Officer — 143,923 $0.00 $0
2026-03-09 TANDY BRADLEY J Officer — 25,586 $0.00 $0
2026-03-09 LANG PATRICIA A Officer — 25,586 $0.00 $0
2026-03-09 KLECKNER JOHN Officer — 14,925 $0.00 $0
2026-03-09 BERRY PHILLIP BENJAMIN BEN Chief Financial Officer — 47,974 $0.00 $0
2026-03-09 ROSS TERRY D Officer — 36,247 $0.00 $0
2026-03-09 VOGT LOUIS Officer — 36,247 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
2,248.05
+6.66%
2,107.62
+23.46%
1,707.20
+9.22%
1,563.10
Operating Revenue
2,248.05
+6.66%
2,107.62
+23.46%
1,707.20
+9.22%
1,563.10
Cost Of Revenue
902.79
-2.60%
926.87
+29.38%
716.42
+3.27%
693.72
Reconciled Cost Of Revenue
782.06
-3.16%
807.60
+27.62%
632.83
+5.42%
600.31
Gross Profit
1,345.26
+13.93%
1,180.76
+19.17%
990.78
+13.96%
869.38
Operating Expense
1,364.13
+6.23%
1,284.18
+23.58%
1,039.15
+8.24%
960.04
Research And Development
120.33
+31.80%
91.30
+21.20%
75.33
+23.84%
60.83
Selling General And Administration
1,070.15
+4.17%
1,027.35
+23.73%
830.30
+7.43%
772.91
Total Expenses
2,266.92
+2.53%
2,211.05
+25.94%
1,755.57
+6.16%
1,653.76
Operating Income
-18.87
+81.76%
-103.43
-113.81%
-48.37
+46.64%
-90.66
Total Operating Income As Reported
-1,124.23
-44.93%
-775.72
-1080.54%
-65.71
+7.68%
-71.18
EBITDA
-830.22
-72.59%
-481.03
-383.41%
169.73
-29.77%
241.69
Normalized EBITDA
275.14
+43.86%
191.26
-1.61%
194.40
+48.24%
131.14
Reconciled Depreciation
294.38
+3.36%
284.80
+31.18%
217.11
-1.18%
219.71
EBIT
-1,124.60
-46.85%
-765.82
-1516.38%
-47.38
-315.53%
21.98
Total Unusual Items
-1,105.36
-64.42%
-672.29
-2625.35%
-24.67
-122.31%
110.55
Total Unusual Items Excluding Goodwill
-1,105.36
-64.42%
-672.29
-2625.35%
-24.67
-122.31%
110.55
Special Income Charges
-1,105.36
-64.42%
-672.29
-2625.35%
-24.67
-2593.01%
-0.92
Other Special Charges
45.82
—
7.33
+144.96%
-16.31
Impairment Of Capital Assets
1,049.75
+62.75%
645.00
0.00
0.00
Restructuring And Mergern Acquisition
9.79
-64.13%
27.29
+57.43%
17.34
+0.64%
17.23
Net Income
-1,184.44
-43.48%
-825.49
-2381.87%
-33.26
-150.23%
-13.29
Pretax Income
-1,159.42
-40.89%
-822.92
-1125.90%
-67.13
-3144.47%
-2.07
Net Non Operating Interest Income Expense
-34.82
+39.01%
-57.10
-189.13%
-19.75
+17.89%
-24.05
Interest Expense Non Operating
34.82
-39.01%
57.10
+189.13%
19.75
-17.89%
24.05
Net Interest Income
-34.82
+39.01%
-57.10
-189.13%
-19.75
+17.89%
-24.05
Interest Expense
34.82
-39.01%
57.10
+189.13%
19.75
-17.89%
24.05
Other Income Expense
-1,105.73
-66.93%
-662.39
-66672.36%
0.99
-99.12%
112.64
Other Non Operating Income Expenses
-0.37
-103.71%
9.89
-61.44%
25.66
+1129.07%
2.09
Gain On Sale Of Security
—
—
—
111.47
Tax Provision
22.29
+396.28%
4.49
+133.80%
-13.29
-136.79%
36.12
Tax Rate For Calcs
0.00
+0.00%
0.00
+6.06%
0.00
-5.71%
0.00
Tax Effect Of Unusual Items
-232.13
-64.42%
-141.18
-2790.53%
-4.88
-121.04%
23.22
Net Income Including Noncontrolling Interests
-1,183.62
-43.50%
-824.82
-2419.98%
-32.73
-178.35%
-11.76
Net Income From Continuing Operation Net Minority Interest
-1,182.53
-42.80%
-828.10
-1423.10%
-54.37
-36.87%
-39.72
Net Income From Continuing And Discontinued Operation
-1,184.44
-43.48%
-825.49
-2381.87%
-33.26
-150.23%
-13.29
Net Income Continuous Operations
-1,181.71
-42.82%
-827.42
-1436.83%
-53.84
-40.98%
-38.19
Net Income Discontinuous Operations
-1.91
-173.39%
2.60
-87.68%
21.11
-20.14%
26.43
Minority Interests
-0.82
-20.77%
-0.68
-28.11%
-0.53
+65.43%
-1.53
Normalized Income
-309.30
-4.15%
-296.99
-758.71%
-34.59
+72.78%
-127.06
Net Income Common Stockholders
-1,184.44
-43.48%
-825.49
-2381.87%
-33.26
-150.23%
-13.29
Diluted EPS
-20.75
-38.98%
-14.93
-2347.54%
-0.61
-144.00%
-0.25
Basic EPS
-20.75
-38.98%
-14.93
-2347.54%
-0.61
-144.00%
-0.25
Basic Average Shares
57.07
+3.22%
55.29
+1.40%
54.53
+2.55%
53.17
Diluted Average Shares
57.07
+3.22%
55.29
+0.56%
54.98
+3.41%
53.17
Diluted NI Availto Com Stockholders
-1,184.44
-43.48%
-825.49
-2381.87%
-33.26
-150.23%
-13.29
Amortization
173.65
+4.90%
165.53
+23.98%
133.52
+5.71%
126.30
Amortization Of Intangibles Income Statement
173.65
+4.90%
165.53
+23.98%
133.52
+5.71%
126.30
Depreciation Amortization Depletion Income Statement
173.65
+4.90%
165.53
+23.98%
133.52
+5.71%
126.30
Depreciation And Amortization In Income Statement
173.65
+4.90%
165.53
+23.98%
133.52
+5.71%
126.30
Line Item Trend 2023-12-31
Total Assets
4,509.33
Current Assets
896.52
Cash Cash Equivalents And Short Term Investments
36.19
Cash And Cash Equivalents
36.19
Receivables
291.48
Accounts Receivable
291.48
Gross Accounts Receivable
301.21
Allowance For Doubtful Accounts Receivable
-9.73
Inventory
468.83
Raw Materials
88.13
Work In Process
39.31
Finished Goods
406.93
Prepaid Assets
28.90
Assets Held For Sale Current
—
Other Current Assets
71.11
Total Non Current Assets
3,612.82
Net PPE
334.30
Gross PPE
576.75
Accumulated Depreciation
-242.45
Properties
0.00
Land And Improvements
6.45
Buildings And Improvements
41.20
Machinery Furniture Equipment
465.60
Other Properties
63.51
Goodwill And Other Intangible Assets
3,188.26
Goodwill
2,060.89
Other Intangible Assets
1,127.36
Other Non Current Assets
90.25
Total Liabilities Net Minority Interest
1,088.63
Current Liabilities
369.61
Payables And Accrued Expenses
273.83
Payables
146.86
Accounts Payable
132.47
Current Accrued Expenses
126.97
Pensionand Other Post Retirement Benefit Plans Current
70.98
Total Tax Payable
14.38
Current Debt And Capital Lease Obligation
21.57
Current Debt
—
Other Current Borrowings
—
Current Capital Lease Obligation
21.57
Current Deferred Liabilities
2.95
Current Deferred Revenue
2.95
Other Current Liabilities
0.28
Total Non Current Liabilities Net Minority Interest
719.03
Liabilities Heldfor Sale Non Current
—
Long Term Debt And Capital Lease Obligation
514.85
Long Term Debt
466.16
Long Term Capital Lease Obligation
48.68
Other Non Current Liabilities
204.18
Stockholders Equity
3,418.39
Common Stock Equity
3,418.39
Capital Stock
0.06
Common Stock
0.06
Share Issued
54.60
Ordinary Shares Number
54.60
Treasury Shares Number
0.00
Additional Paid In Capital
2,900.75
Retained Earnings
542.47
Gains Losses Not Affecting Retained Earnings
-24.88
Minority Interest
2.31
Other Equity Adjustments
-24.88
Total Equity Gross Minority Interest
3,420.70
Total Capitalization
3,884.56
Working Capital
526.91
Invested Capital
3,884.56
Total Debt
536.42
Net Debt
429.97
Capital Lease Obligations
70.25
Net Tangible Assets
230.14
Tangible Book Value
230.14
Current Provisions
—
Interest Payable
3.77
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
217.29
+91.44%
113.50
-15.92%
134.99
+341.65%
-55.86
Cash Flow From Continuing Operating Activities
217.29
+91.44%
113.50
-15.92%
134.99
+341.65%
-55.86
Net Income From Continuing Operations
-1,183.62
-43.50%
-824.82
-2419.98%
-32.73
-178.35%
-11.76
Depreciation Amortization Depletion
294.38
+3.36%
284.80
+31.18%
217.11
-1.18%
219.71
Depreciation
294.38
+3.36%
284.80
+31.18%
217.11
-1.18%
219.71
Amortization Cash Flow
—
—
140.20
—
Depreciation And Amortization
294.38
+3.36%
284.80
+31.18%
217.11
-1.18%
219.71
Amortization Of Intangibles
—
—
140.20
—
Other Non Cash Items
7.38
+39.89%
5.27
+92.34%
2.74
-30.07%
3.92
Pension And Employee Benefit Expense
—
—
0.00
0.00
Stock Based Compensation
32.92
+10.99%
29.66
-12.93%
34.06
-12.55%
38.95
Asset Impairment Charge
1,049.75
+61.42%
650.31
0.00
0.00
Deferred Tax
-2.23
+77.78%
-10.02
+63.46%
-27.41
-533.73%
6.32
Deferred Income Tax
-2.23
+77.78%
-10.02
+63.46%
-27.41
-533.73%
6.32
Operating Gains Losses
1.46
-88.19%
12.34
+139.16%
-31.52
+65.26%
-90.72
Gain Loss On Investment Securities
—
—
—
-111.47
Unrealized Gain Loss On Investment Securities
1.79
+108.88%
-20.12
0.00
0.00
Net Foreign Currency Exchange Gain Loss
0.00
-100.00%
11.12
+145.75%
-24.31
0.00
Gain Loss On Sale Of PPE
1.46
+19.70%
1.22
+108.38%
-14.54
-4230.40%
0.35
Change In Working Capital
15.46
+211.03%
-13.93
+48.92%
-27.27
+87.73%
-222.29
Change In Receivables
-10.75
+81.15%
-57.05
-249.66%
-16.32
+63.89%
-45.19
Changes In Account Receivables
-10.75
+81.15%
-57.05
-249.66%
-16.32
+63.89%
-45.19
Change In Inventory
-11.98
-130.66%
39.07
+257.95%
-24.74
+79.18%
-118.79
Change In Payables And Accrued Expense
-1.14
-108.13%
13.98
+310.64%
-6.64
+43.95%
-11.84
Change In Payable
-1.14
-108.13%
13.98
+310.64%
-6.64
+43.95%
-11.84
Change In Account Payable
-1.14
-108.13%
13.98
+310.64%
-6.64
+43.95%
-11.84
Change In Other Working Capital
39.34
+496.08%
-9.93
-148.63%
20.42
+143.95%
-46.46
Investing Cash Flow
-179.37
+81.23%
-955.47
-294.06%
-242.47
-37.46%
-176.39
Cash Flow From Continuing Investing Activities
-179.37
+81.23%
-955.47
-294.06%
-242.47
-37.46%
-176.39
Net PPE Purchase And Sale
-197.38
-9.22%
-180.71
-101.57%
-89.65
+12.71%
-102.70
Purchase Of PPE
-197.38
-9.22%
-180.71
-47.86%
-122.22
-15.91%
-105.45
Sale Of PPE
0.00
0.00
-100.00%
32.57
+1086.13%
2.75
Capital Expenditure
-197.38
-9.22%
-180.71
-47.86%
-122.22
-15.91%
-105.45
Net Investment Purchase And Sale
1.60
+133.04%
-4.84
0.00
0.00
Purchase Of Investment
—
-4.84
0.00
0.00
Net Business Purchase And Sale
16.40
+102.13%
-769.91
-403.82%
-152.81
-107.39%
-73.68
Purchase Of Business
-26.86
+96.51%
-769.91
-403.82%
-152.81
-107.39%
-73.68
Gain Loss On Sale Of Business
—
—
—
—
Financing Cash Flow
-52.40
-106.19%
846.82
+562.63%
127.80
+127.48%
-465.13
Cash Flow From Continuing Financing Activities
-52.40
-106.19%
846.82
+562.63%
127.80
+127.48%
-465.13
Net Issuance Payments Of Debt
-36.92
-104.30%
859.23
+295.60%
217.19
+113.65%
-1,591.16
Issuance Of Debt
544.00
-60.92%
1,392.00
+52.13%
915.00
+77.67%
515.00
Repayment Of Debt
-580.92
-9.04%
-532.77
+23.65%
-697.80
+66.87%
-2,106.16
Long Term Debt Issuance
544.00
-60.92%
1,392.00
+52.13%
915.00
+77.67%
515.00
Long Term Debt Payments
-580.92
-9.04%
-532.77
+23.65%
-697.80
+66.87%
-2,106.16
Net Long Term Debt Issuance
-36.92
-104.30%
859.23
+295.60%
217.19
+113.65%
-1,591.16
Short Term Debt Issuance
—
—
455.00
-11.65%
515.00
Short Term Debt Payments
—
—
-697.80
+50.85%
-1,419.88
Net Short Term Debt Issuance
—
—
-242.81
+73.17%
-904.88
Net Common Stock Issuance
1.32
-29.67%
1.87
+5.52%
1.78
-69.45%
5.81
Proceeds From Stock Option Exercised
—
—
—
—
Net Other Financing Charges
-16.79
-17.60%
-14.28
+84.34%
-91.17
-108.14%
1,120.22
Changes In Cash
-14.48
-398.39%
4.85
-76.12%
20.32
+102.91%
-697.38
Effect Of Exchange Rate Changes
2.70
+277.98%
-1.52
-792.69%
0.22
-90.48%
2.30
Beginning Cash Position
48.17
+7.44%
44.83
+84.53%
24.30
-96.62%
719.37
End Cash Position
36.39
-24.45%
48.17
+7.44%
44.83
+84.53%
24.30
Free Cash Flow
19.92
+129.63%
-67.21
-626.52%
12.77
+107.91%
-161.31
Interest Paid Supplemental Data
27.45
-47.04%
51.83
+217.41%
16.33
-55.98%
37.09
Income Tax Paid Supplemental Data
18.38
+70.21%
10.80
-13.72%
12.52
-60.09%
31.36
Common Stock Issuance
1.32
-29.67%
1.87
+5.52%
1.78
-69.45%
5.81
Issuance Of Capital Stock
1.32
-29.67%
1.87
+5.52%
1.78
-69.45%
5.81
Sale Of Business
43.26
0.00
0.00
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category